Growth Hormone
Hexarelin
A six-amino-acid growth-hormone-releasing peptide investigated for potent acute GH release and ancillary cardiovascular research models.
Quick facts
Molecular weight
887 Da
Half-life
1.17 h
Frequency
daily
Admins / wk
7
Routes
SubQ
Typical dose
100 mcg–300 mcg
Mechanism & positioning
A six-amino-acid growth-hormone-releasing peptide investigated for potent acute GH release and ancillary cardiovascular research models.
Researched for: GHRP-class GH release, cardiac protection (research models).
Reconstitution defaults
Default vial
5 mg
BAC water
2 mL
Concentration
2500 mcg/mL
Doses per vial
~50
Other stocked vial sizes: 10 mg.
Calculate with this peptide
Documented pairwise interactions
- warning
Hexarelin + Ipamorelin
Two GHRP-class agents at the same ghrelin receptor; redundant mechanism with additive cortisol/prolactin risk for the older GHRP.
References
- Imbimbo BP et al., Eur J Clin Pharmacol, 1994.
Related peptides in the Growth Hormone class
CJC-1295 (no-DAC)
A growth-hormone-releasing-hormone analog researched for its ability to stimulate endogenous pulsatile GH secretion, often paired with a GHRP.
CJC-1295 (with DAC)
CJC-1295 conjugated to a Drug Affinity Complex linker that binds serum albumin, extending half-life to roughly eight days and producing a steady GHRH-axis baseline rather than pulsatile peaks.
Ipamorelin
A selective ghrelin-mimetic pentapeptide investigated for triggering GH release with minimal off-target hormonal effects.
Tesamorelin
A stabilised GHRH analog researched extensively in HIV-associated lipodystrophy for its visceral-fat-reducing properties.
Sermorelin
The original 1-29 amino-acid fragment of GHRH; researched for restoring pulsatile growth-hormone secretion via direct hypothalamic-pituitary axis stimulation.
IGF1-LR3
A long-acting IGF-1 analog with an extended N-terminal sequence and an arginine substitution that reduces IGF-binding-protein affinity, producing a substantially longer circulating half-life than native IGF-1.